Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Paul Schimmel


Dr. Paul Schimmel is a Co-Founder and serves as Member of Scientific Advisory Board of Metabolon. He also serves as Advisor at Cardinal Partners. Dr. Schimmel is the Founder and serves as a Board Member at Alnylam Pharmaceuticals. He co-founded and served as the Director at aTyr Pharma. He is a scientific founder of Alnylam and has served as a member of Alnylam Pharmaceuticals board of directors since June 2002. As required by Alnylam Pharmaceuticals Corporate Governance Guidelines, Dr. Schimmel offered his resignation to the board of directors upon reaching the age of 75. After considering Dr. Schimmel's many contributions to the board of directors and his specialized experience in areas critical to Alnylam Pharmaceuticals company, Alnylam Pharmaceuticals board of directors determined not to accept Dr. Schimmel's resignation and is recommending Dr. Schimmel for re-election as a director. Dr. Schimmel has been the Ernest and Jean Hahn Professor of Molecular Biology and Chemistry and a member of the faculty of the Skaggs Institute for Chemical Biology at the Scripps Research Institute since 1997. Previously, he was the John D. and Catherine T. MacArthur Professor of Biochemistry and Biophysics at the Massachusetts Institute of Technology. Dr. Schimmel is a member of the National Academy of Sciences, the Institute of Medicine, the National Academy of Inventors and the American Academy of Arts and Sciences. Key Contributions to the Board Dr. Schimmel is a noted academic scholar, and his knowledge and experience offer a critical scientific perspective to Alnylam Pharmaceuticals board. Dr. Schimmel has authored or co-authored more than 480 scientific papers, and has been active in many scientific and academic organizations and committees. Having a longstanding interest in the applications of basic biomedical research to human health, Dr. Schimmel holds several patents and is a co-founder or founding director of a number of biotechnology companies, of which seven, including Alnylam, became publicly traded. As one of Alnylam Pharmaceuticals scientific founders, Dr. Schimmel's insight and scientific expertise are invaluable assets to Alnylam Pharmaceuticals board when evaluating Alnylam Pharmaceuticals strategy and unique challenges as one of the first companies focused on the discovery and development of therapeutics based on RNA interference, or RNAi.

Primary Investor Type
Angel (individual)

Paul Schimmel Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Company Stage Lead Partner
000000 00000000000 06-Mar-2015 00000 00000 00.00 Biotechnology Clinical Trials - Phase 2 0000 00000000 00.0
To view this investor’s complete investment and acquisition history, request access »
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Paul Schimmel’s full profile, request a free trial.

Paul Schimmel Team (1)

Name Title Deals Funds Boards Office Contact
Paul Schimmel Ph.D Angel Investor 0 0 London, United Kingdom